Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Patent number: 8476409Abstract: Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.Type: GrantFiled: April 19, 2012Date of Patent: July 2, 2013Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
-
Patent number: 8475792Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: October 24, 2012Date of Patent: July 2, 2013Assignees: MedImmune, LLC, Board of Regents, The Texas University SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
-
Patent number: 8470330Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.Type: GrantFiled: July 28, 2010Date of Patent: June 25, 2013Assignees: PSMA Development Company, LLC, Amgen Fremont Inc.Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
-
Patent number: 8470793Abstract: Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed.Type: GrantFiled: September 25, 2008Date of Patent: June 25, 2013Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Zvi Fishelson, David Pilzer
-
Patent number: 8466260Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: March 31, 2010Date of Patent: June 18, 2013Assignee: Genentech, Inc.Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
-
Patent number: 8461304Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: June 9, 2010Date of Patent: June 11, 2013Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Patent number: 8461308Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.Type: GrantFiled: October 13, 2010Date of Patent: June 11, 2013Assignee: Medarex, Inc.Inventors: Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
-
Patent number: 8455625Abstract: Conjugate for targeting therapeutic or diagnostic agent or drug to cells or tissues in a body, e.g. areas of neoplastic growth or angiogenesis. Use of conjugate for in vivo diagnosis or therapy e.g. inhibiting tumor growth or metastasis, inhibiting angiogenesis and/or treating cancer. Conjugate comprises therapeutic or diagnostic agent as oligomeric protein e.g. heterodimeric protein, wherein first and second subunits of protein are each conjugated to a specific binding member e.g. an antibody fragment such as scFv. Subunits of oligomer may be conjugated to specific binding members as fusion proteins. Conjugate may comprise IL-12 heterodimer having two subunits, each subunit fused to scFv L19 or TN11 for targeting IL-12 to extracellular matrix components associated with neoplastic growth and angiogenesis.Type: GrantFiled: May 3, 2006Date of Patent: June 4, 2013Assignee: Philogen S.p.A.Inventors: Dario Neri, Verena Gafner, Cornelia Halin
-
Publication number: 20130129718Abstract: Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same.Type: ApplicationFiled: November 20, 2012Publication date: May 23, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Publication number: 20130129731Abstract: An anti c-Met antibody or antigen-binding fragment thereof comprising a heavy-chain variable region having heavy-chain complementarity determining region (CDR) amino acid sequences of SEQ ID NOs: 1, 2 and 3, and a light-chain variable region having light-chain CDR amino acid sequences of SEQ ID NOs: 4, 5, and 6; and a method of wound healing, tissue regeneration, or cell proliferation comprising administration of same; as well as related compositions and methods.Type: ApplicationFiled: November 16, 2012Publication date: May 23, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventor: Samsung Electronics Co., Ltd.
-
Patent number: 8444972Abstract: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.Type: GrantFiled: August 5, 2010Date of Patent: May 21, 2013Assignee: University of MassachusettsInventors: Kenneth L. Rock, Dancella Fernandes
-
Patent number: 8445211Abstract: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.Type: GrantFiled: July 10, 2008Date of Patent: May 21, 2013Assignees: bioMerieux, Centre National de la Recherche Scientifique, Institut CurieInventors: Monique Arpin, Nicole Battail-Poirot, Corinne Beaulieu, Jean-Philippe Charrier, Genevieve Choquet-Kastylevsky
-
Patent number: 8445444Abstract: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).Type: GrantFiled: October 26, 2011Date of Patent: May 21, 2013Assignee: Phigenix, Inc.Inventor: Carlton D. Donald
-
Patent number: 8440798Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: GrantFiled: October 4, 2007Date of Patent: May 14, 2013Assignees: Københavns Universitet, Cancer Research Technology LimitedInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Patent number: 8435511Abstract: The invention provides hepsin antibodies, and compositions comprising and methods of using these antibodies.Type: GrantFiled: October 21, 2010Date of Patent: May 7, 2013Assignee: Genentech, Inc.Inventors: Rajkumar Ganesan, Daniel Kirchhofer, Paul M. Moran, Yingnan Zhang
-
Publication number: 20130109844Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: September 14, 2012Publication date: May 2, 2013Inventors: Liliane GOETSCH, Thierry Wurch, Bes Cédric
-
Patent number: 8425903Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: May 15, 2012Date of Patent: April 23, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Publication number: 20130095128Abstract: Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.Type: ApplicationFiled: March 30, 2011Publication date: April 18, 2013Applicant: ONCOTHERAPY SCIENCE INCInventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20130089542Abstract: An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject.Type: ApplicationFiled: October 5, 2012Publication date: April 11, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventor: Samsung Electronics Co. Ltd.
-
Publication number: 20130089556Abstract: An anti c-Met antibody, a composition comprising the antibody, and a method for preventing or treating cancer by administering the composition is provided.Type: ApplicationFiled: August 20, 2012Publication date: April 11, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Kwang Ho CHEONG, Seunghyun LEE, Geun Woong KIM, Kyung-Ah KIM, Young Mi OH, Saet Byoul LEE, Soo-yeon JUNG, Yunju JEONG, Young Kue HAN
-
Publication number: 20130089544Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies.Type: ApplicationFiled: December 11, 2012Publication date: April 11, 2013Applicant: MedImmune LimitedInventor: MedImmune Limited
-
Publication number: 20130089557Abstract: An antibody or antigen binding fragment thereof that specifically binds to an epitope in a SEMA domain of c-Met protein, and pharmaceutical compositions, methods, kits, nucleic acids, and cells related thereto.Type: ApplicationFiled: October 5, 2012Publication date: April 11, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventor: Samsung Electronics Co., Ltd.
-
Patent number: 8414890Abstract: Isolated human antibodies or antigen-binding fragments thereof, which specifically bind to human RANKL and block hRANKL binding to a RANK receptor, are provided. The antibodies are useful in preventing or treating disorders and/or diseases, which are associated with RANKL/RANK interactions, including bone disorders or cancer.Type: GrantFiled: August 19, 2009Date of Patent: April 9, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Aris N. Economides, Regina Raz
-
Patent number: 8414896Abstract: The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.Type: GrantFiled: November 12, 2010Date of Patent: April 9, 2013Assignee: Symphogen A/SInventors: Mikkel Wandahl Pedersen, Lucilla Steinaa, Allan Jensen, Klaus Koefoed, Per-Johan Meijer, Robert Carlsson, Charles Pyke, Lars Sogaard Nielsen
-
Patent number: 8410252Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: August 24, 2010Date of Patent: April 2, 2013Assignee: Immunex CorporationInventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage
-
Patent number: 8404810Abstract: This invention relates to the polynucleotides and the encoded polypeptides, including novel sequences, of human or non-human primate genes that are amplified in breast and/or other tumor tissues melanoma, as compared to the corresponding normal tissue. The invention also relates to modulators of such polynucleotides and polypeptides, for example, antibodies, that specifically bind to and/or interfere with the activity of this polypeptide, polynucleotide, its fragments, variants, and antagonists. The invention further relates to compositions containing such a polypeptide, polynucleotide, or modulators thereof and uses of such compositions in methods of treating or preventing cancer, by detecting this polynucleotide, polypeptide, or antibodies thereto in patient samples. The invention also provides diagnostic tests for breast cancer and melanoma, by identifying polypeptides and polynucleotides encoded by the cDNA sequence of the invention that correlate with those disorders.Type: GrantFiled: February 20, 2007Date of Patent: March 26, 2013Assignee: Five Prime Therapeutics, Inc.Inventors: Kevin Hestir, Justin Wong
-
Patent number: 8404233Abstract: The present invention provides a binding protein capable of binding to delta-like ligand 4 (DLL4) as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.Type: GrantFiled: May 15, 2008Date of Patent: March 26, 2013Assignee: Smart Targeting LimitedInventors: Makoto Sunamura, Hideo Yagita
-
Patent number: 8404239Abstract: The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same.Type: GrantFiled: September 30, 2009Date of Patent: March 26, 2013Assignee: Genentech, Inc.Inventors: Christian W. Siebel, Yan Wu
-
Patent number: 8399618Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.Type: GrantFiled: December 23, 2011Date of Patent: March 19, 2013Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
-
Patent number: 8399622Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.Type: GrantFiled: November 18, 2011Date of Patent: March 19, 2013Assignee: Clarient Diagnostic Services, Inc.Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
-
Patent number: 8399202Abstract: Novel immuno-interactive fragments of the ?C portion of a mammalian inhibin ? subunit, together with their variants and derivatives, produce antigen-binding molecules that are interactive with the ?C portion, and which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.Type: GrantFiled: March 30, 2009Date of Patent: March 19, 2013Assignee: Prince Henry's Institute of Medical ResearchInventors: David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
-
Publication number: 20130064814Abstract: The present disclosure provides methods and compositions for inhibiting the proliferation, differentiation, or development of stem cells and cancer stem cells in a patient in need thereof. The methods involve administering to a patient a therapeutically effective amount of an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. The compositions include an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. Specific antagonists such as antibodies and antisense oligonucleotides, and combination therapy with one or more additional anti-cancer agents, are also provided by this disclosure. Such methods, antagonists, and compositions can be useful, for example, in the treatment of cancer.Type: ApplicationFiled: September 11, 2012Publication date: March 14, 2013Inventor: Lloyd S. Gray
-
Patent number: 8394926Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.Type: GrantFiled: December 21, 2006Date of Patent: March 12, 2013Assignee: Micromet AGInventors: Ralf Lutterbüse, Petra Mayer, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger
-
Patent number: 8394924Abstract: The present invention features engineered proteins that include a first polypeptide that specifically binds a first target (e.g., a cellular target, such as a cell-surface antigen) and a second polypeptide that selectively binds an activating FcR.Type: GrantFiled: October 23, 2009Date of Patent: March 12, 2013Assignee: Massachusetts Institute of TechnologyInventors: K. Dane Wittrup, Shanshan Wu Howland
-
Patent number: 8394376Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: GrantFiled: December 7, 2010Date of Patent: March 12, 2013Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Publication number: 20130058935Abstract: Antibodies that specifically bind to an epitope on the extracellular domain of TEM7R are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. The antibodies may be used in methods for treating tumors and for inhibiting angiogenesis in tumors.Type: ApplicationFiled: May 11, 2011Publication date: March 7, 2013Applicant: Fox Chase Cancer CenterInventors: Hossein Borghaei, Louis M. Weiner
-
Publication number: 20130058864Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: November 1, 2012Publication date: March 7, 2013Applicant: Millennium Pharmaceuticals, Inc.Inventor: Millennium Pharmaceuticals, Inc.
-
Patent number: 8389227Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: June 5, 2009Date of Patent: March 5, 2013Assignees: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recera I Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres
-
Patent number: 8389694Abstract: An isolated and characterized monoclonal antibody (“440c”) prepared by immunizing Wistar/CRL rats subcutaneously with purified rat bone marrow IPC, fusing popliteal lymph nodes of the rats with SP2/0 myeloma spleen cells and differentially selecting for hybridome supernatants that successfully stain bone marrow derived IPC and fractions thereof using CD11c+ spleen cells and, differentially selecting for hybridoma supernatants from the CD11c+ spleen cells that successfully stain only CD 11 c+/Ly6c+/CD 11 b?/B220+ splenocytes to provide the monoclonal antibody.Type: GrantFiled: November 23, 2004Date of Patent: March 5, 2013Inventors: Amanda L. Blasius, Marco Colonna, Marina Cella
-
Patent number: 8383122Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.Type: GrantFiled: October 8, 2010Date of Patent: February 26, 2013Assignee: ImmunoGen, Inc.Inventors: Yong Dai, Yong Wang, Shengjin Jin, Deborah H. Meshulam, Godfrey W. Amphlett
-
Patent number: 8378079Abstract: Antibodies that which specifically bind to mammalian cytokine-like polypeptide, called Zcyto10, are described. The antibodies include monoclonal antibodies and those that where the antibody is an antigen-binding fragment. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.Type: GrantFiled: January 30, 2012Date of Patent: February 19, 2013Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Betty A. Haldeman, Angelika Grossman
-
Patent number: 8372402Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: GrantFiled: January 13, 2012Date of Patent: February 12, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Madaline Chirica, Robert A. Kastelein, Kevin Moore, Christi L. Parham
-
Publication number: 20130034558Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.Type: ApplicationFiled: January 26, 2011Publication date: February 7, 2013Applicant: SHANGHAI CANCER INSTITUTEInventors: Zonghai Li, Hai Wang, Min Zhou, Xiaorong Pan, Jianren Gu, Shengli Yang
-
Patent number: 8367805Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.Type: GrantFiled: December 22, 2008Date of Patent: February 5, 2013Assignee: Xencor, Inc.Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
-
Patent number: 8367353Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: GrantFiled: March 6, 2009Date of Patent: February 5, 2013Assignee: Roche MTM Laboratories AGInventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20130028900Abstract: The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof.Type: ApplicationFiled: October 26, 2010Publication date: January 31, 2013Applicant: Beth Israel Deaconess Medical Center Inc.Inventors: Kun Ping Lu, Xiao Zhen Zhao
-
Patent number: 8362210Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.Type: GrantFiled: January 19, 2011Date of Patent: January 29, 2013Assignee: Xencor, Inc.Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
-
Patent number: 8357494Abstract: The invention concerns anti-clusterin oligoclonal antibodies able to recognize and bind in a selective and specific way antigenic epitopes of clusterin isoforms to be used in tumors diagnosis and in the prediction of their malignancy grade, diagnostic method and related kits.Type: GrantFiled: February 17, 2005Date of Patent: January 22, 2013Assignees: Universita' Delgi Studi “Tor Vergate”, Institute Fisioterapici OspitalieriInventors: Luigi Giusto Spagnoli, Sabina Pucci, Elena Bonanno, Flavia Pichiorri, Gennaro Citro
-
Patent number: 8354508Abstract: The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.Type: GrantFiled: July 20, 2007Date of Patent: January 15, 2013Assignee: Diadexus, Inc.Inventors: Gundo Diedrich, Paul Levi Miller, Jackie Papkoff, Astrid Strelow
-
Patent number: 8349585Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: GrantFiled: April 14, 2011Date of Patent: January 8, 2013Assignee: Alper Biotech, LLCInventor: Özge Alper